Augmedix, Inc. (NASDAQ:AUGX) Short Interest Update

Augmedix, Inc. (NASDAQ:AUGX) was the target of a large growth in short interest in August. As of August 15th, there was short interest totalling 1,570,000 shares, a growth of 98.6% from the July 31st total of 790,700 shares. Currently, 3.2% of the shares of the stock are sold short. Based on an average daily volume of 938,700 shares, the days-to-cover ratio is presently 1.7 days.

Hedge Funds Weigh In On Augmedix

Several institutional investors and hedge funds have recently made changes to their positions in the business. Oppenheimer Asset Management Inc. bought a new position in Augmedix during the 1st quarter worth approximately $56,000. SG Americas Securities LLC purchased a new position in shares of Augmedix in the first quarter worth $57,000. Symmetry Peak Management LLC bought a new stake in Augmedix during the 4th quarter valued at $88,000. Norden Group LLC boosted its position in Augmedix by 50.2% during the 1st quarter. Norden Group LLC now owns 19,152 shares of the company’s stock valued at $78,000 after buying an additional 6,401 shares during the period. Finally, Thompson Davis & CO. Inc. bought a new stake in Augmedix in the 4th quarter worth $120,000. Institutional investors own 87.11% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AUGX. William Blair cut Augmedix from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 19th. B. Riley cut shares of Augmedix from a “strong-buy” rating to a “hold” rating and decreased their price objective for the stock from $3.00 to $2.35 in a research report on Friday, July 19th. Lake Street Capital reaffirmed a “hold” rating on shares of Augmedix in a research note on Monday, July 22nd. Maxim Group lowered shares of Augmedix from a “buy” rating to a “hold” rating and set a $5.00 price target on the stock. in a report on Tuesday, May 14th. Finally, Evercore ISI downgraded shares of Augmedix from an “outperform” rating to an “inline” rating and dropped their price objective for the stock from $5.00 to $1.50 in a report on Tuesday, May 14th. Four research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $3.09.

Augmedix Price Performance

NASDAQ AUGX traded up $0.03 on Thursday, reaching $2.32. 384,465 shares of the company’s stock traded hands, compared to its average volume of 706,921. The stock has a market cap of $113.61 million, a PE ratio of -5.40 and a beta of -0.22. Augmedix has a 12 month low of $0.73 and a 12 month high of $6.25. The stock has a 50-day simple moving average of $1.73 and a 200 day simple moving average of $2.48. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.04 and a quick ratio of 2.04.

Augmedix Company Profile

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.